DI IASIO, Maria Grazia
 Distribuzione geografica
Continente #
NA - Nord America 2.696
EU - Europa 595
AS - Asia 475
OC - Oceania 2
SA - Sud America 1
Totale 3.769
Nazione #
US - Stati Uniti d'America 2.695
CN - Cina 242
UA - Ucraina 179
SG - Singapore 120
DE - Germania 110
TR - Turchia 99
GB - Regno Unito 86
IT - Italia 81
SE - Svezia 48
FI - Finlandia 41
BE - Belgio 13
NL - Olanda 11
FR - Francia 8
RU - Federazione Russa 5
CZ - Repubblica Ceca 4
ID - Indonesia 4
IR - Iran 4
ES - Italia 3
LT - Lituania 3
AU - Australia 2
VN - Vietnam 2
AZ - Azerbaigian 1
BR - Brasile 1
GR - Grecia 1
IL - Israele 1
IN - India 1
JP - Giappone 1
MD - Moldavia 1
MX - Messico 1
PL - Polonia 1
Totale 3.769
Città #
Fairfield 408
Woodbridge 385
Houston 226
Jacksonville 199
Ashburn 180
Chandler 169
Ann Arbor 140
Seattle 134
Wilmington 121
Cambridge 104
Singapore 99
Santa Clara 80
Izmir 66
Beijing 52
Nanjing 47
Princeton 40
San Diego 39
New York 32
Ferrara 31
Boardman 28
Shanghai 22
Falls Church 18
Nanchang 16
Milan 15
Changsha 13
Brussels 12
Shenyang 12
Hebei 11
Los Angeles 11
San Mateo 11
Tianjin 11
Dearborn 10
Jiaxing 7
London 7
Norwalk 7
Orange 7
Zhengzhou 7
Dronten 6
Jinan 6
Verona 6
Washington 6
Auburn Hills 5
Bremen 5
Helsinki 5
Kunming 5
Leawood 5
Mountain View 5
Munich 5
Augusta 4
Brno 4
Jakarta 4
Ardabil 3
Frankfurt am Main 3
Haikou 3
Monmouth Junction 3
Ningbo 3
Padova 3
Philadelphia 3
Alicante 2
Des Moines 2
Dong Ket 2
Düsseldorf 2
Indiana 2
Prescot 2
Redmond 2
Tappahannock 2
Acton 1
Addison 1
Atlanta 1
Baku 1
Bologna 1
Changchun 1
Chaozhou 1
Chisinau 1
Edinburgh 1
Fuzhou 1
Hangzhou 1
Islington 1
Jinhua 1
Kilburn 1
Lanzhou 1
Logan 1
Marienheide 1
Mexico City 1
Monselice 1
New Bedfont 1
Paris 1
Qinzhou 1
Redwood City 1
Rouen 1
Saint Petersburg 1
San Francisco 1
Secaucus 1
Senigallia 1
Stockholm 1
Taiyuan 1
Taizhou 1
Tel Aviv 1
Tokyo 1
Veranopolis 1
Totale 2.919
Nome #
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells 148
Nutlin-3 upregulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feed-back anti-apoptotic mechanism 131
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status 129
TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release 127
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells 118
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 118
Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells 115
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70 114
Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function 112
Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells 112
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency 111
HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity 109
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain 106
Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin 106
Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells 104
The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells 104
The oncogene DEK promotes leukemic cell survival and is downregulated by both nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells 101
null 100
The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies 100
Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients 99
null 98
null 98
null 97
TNFRSF11B (tumor necrosis factor receptor superfamily, member 11b) 96
SOCS1 is significantly up-regulated in Nutlin-3-treated p53 wild-type B chronic lymphocytic leukemia (BCLL) samples and shows an inverse correlation with miR-155 94
Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region 94
null 89
Activation of the p53 pathway down-regulates the osteoprotegerin (OPG) expression and release by vascular endothelial cells. 89
Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma 83
null 83
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms 75
null 69
Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to Nutlin-3 induces a characteristic gene expression profile, which correlates with Nutlin-3-mediated cytotoxicity 68
TNFSF10 (tumor necrosis factor Ligand) surfamily,member 10) 60
null 55
Risk of venous thromboembolism and stroke associated with oral contraceptives. Role of congenital thrombophilias 53
The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia 39
C reactive protein down-regulates TNF-related apoptosis inducing ligand expression in human peripheral monocytes via an Egr-1 dependent pathway. 38
Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages 33
miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. 30
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women 29
Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. 26
Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes 23
Nutlin-3 downregulates the expression of the Oncogene TCL1 in primary B Chronic Lymphocytic Leukemic cells. 20
Totale 3.803
Categoria #
all - tutte 16.536
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.536


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020544 0 0 0 0 60 95 80 93 70 80 53 13
2020/2021535 47 64 14 83 17 51 18 54 10 59 89 29
2021/2022449 12 60 27 23 22 20 33 22 12 27 52 139
2022/2023398 41 20 20 41 66 57 11 32 54 7 28 21
2023/2024149 23 13 7 3 6 29 8 17 1 4 2 36
2024/2025270 23 21 64 44 118 0 0 0 0 0 0 0
Totale 3.803